Your browser doesn't support javascript.
loading
The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors.
Wang, Yujie; Gao, Peng; Hao, Zhibin; Chen, Ling; Li, Xiaoxiao; Jiao, Yuan; Liu, Jingyu; Li, Jie; Zhang, Yingyi; Peng, Xiaobo; Ning, Beifang; Zhan, Xianbao.
Afiliación
  • Wang Y; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Gao P; Clinical Cancer Institute, Center for Translational Medicine, Naval Military Medical University, Shanghai, China.
  • Hao Z; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Chen L; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Li X; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Jiao Y; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Liu J; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Li J; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Zhang Y; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Peng X; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Ning B; Department of Gastroenterology, Changzheng Hospital, Naval Military Medical University, Shanghai, China.
  • Zhan X; Department of Oncology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Front Oncol ; 12: 1054598, 2022.
Article en En | MEDLINE | ID: mdl-36439457
In recent years, numerous studies have demonstrated that the tumor immune microenvironment (TIME) is capable of regulating the growth of tumors, and tumor-infiltrating immune cells in the TIME can affect the prognosis and treatment responses of patients. Consequently, therapies targeting these immune cells have emerged as important antitumor treatments. As a crucial componet of the perioperative treatment of malignant tumors, neoadjuvant chemotherapy (NACT) can improve the surgical resection rate and prognosis of patients and is a suitable clinical model to evaluate the effect of chemotherapy on the TIME. To provide a rationale for developing valid combinational therapies, this review summarizes the impact of NACT on the TIME, the relationship between tumor-infiltrating immune cells and treatment responses of patients, and the prognostic value of these infiltrating immune cells.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China
...